Elanco Animal Health (ELAN)

Elanco Animal Health Incorporated is a global leader in animal health dedicated to innovating and delivering products and services to prevent and treat disease in farm animals and pets, creating value for farmers, pet owners, veterinarians, stakeholders, and society as a whole. With nearly 70 years of animal health heritage, it is committed to helping its customers improve the health of animals in their care, while also making a meaningful impact on its local and global communities. It is driven by its vision of Food and Companionship Enriching Life and our Elanco Healthy Purpose™ Sustainability/ESG Pledges - all to advance the health of animals, people and the planet.

Company profile

Jeffrey Simmons
Fiscal year end
Aratana Therapeutics, Inc. • ChemGen Corporation • Dista Products Limited • Elanco (Shanghai) Animal Health Co., Ltd. • Elanco (Taiwan) Animal Health Co. Ltd. • Elanco (Thailand) Ltd. • Elanco Animal Health Holdings BV • Elanco Animal Health (Pty) Ltd. • Elanco Animal Health UK Limited • Elanco Animal Health Korea, Co., Ltd. ...

ELAN stock data


8 Aug 22
1 Oct 22
31 Dec 22
Quarter (USD) Jun 22 Mar 22 Dec 21 Sep 21
Cost of revenue
Operating income
Operating margin
Net income
Net profit margin
Cash on hand
Change in cash
Diluted EPS
Annual (USD) Dec 21 Dec 20 Dec 19 Dec 18
Cost of revenue
Operating income
Operating margin
Net income
Net profit margin
Cash on hand
Change in cash
Diluted EPS
Cash burn rate (est.) Burn method: Change in cash Burn method: Operating income Burn method: FCF (opex + capex)
Last Q Avg 4Q Last Q Avg 4Q Last Q Avg 4Q
Cash on hand (at last report) 507M 507M 507M 507M 507M 507M
Cash burn (monthly) (no burn) 6.08M 6M 16.5M (no burn) (no burn)
Cash used (since last report) n/a 18.6M 18.35M 50.46M n/a n/a
Cash remaining n/a 488.4M 488.65M 456.54M n/a n/a
Runway (months of cash) n/a 80.3 81.4 27.7 n/a n/a

Beta Read what these cash burn values mean

Date Owner Security Transaction Code Indirect 10b5-1 $Price #Shares $Value #Remaining
9 Sep 22 Paul Herendeen Common Stock Buy Acquire P No No 15.025 10,000 150.25K 17,307
9 Sep 22 Rajeev A. Modi Common Stock Buy Acquire P No No 14.9 6,700 99.83K 41,157
9 Sep 22 R David Hoover Common Stock Buy Acquire P Yes No 15.1807 20,000 303.61K 145,000
9 Sep 22 Jeffrey N Simmons Common Stock Buy Acquire P Yes No 14.5382 30,000 436.15K 30,000
31 Aug 22 John P Bilbrey Common Stock Grant Acquire A No No 15.13 583.829 8.83K 11,696.65
34.9% owned by funds/institutions
13F holders Current Prev Q Change
Total holders 425 457 -7.0%
Opened positions 58 58
Closed positions 90 67 +34.3%
Increased positions 162 174 -6.9%
Reduced positions 137 145 -5.5%
13F shares Current Prev Q Change
Total value 10.91B 14.38B -24.1%
Total shares 482.49M 484.53M -0.4%
Total puts 751.5K 1.32M -43.2%
Total calls 669.7K 930.4K -28.0%
Total put/call ratio 1.1 1.4 -21.1%
Largest owners Shares Value Change
Dodge & Cox 49.21M $965.92M +72.1%
Vanguard 42.48M $833.81M +2.5%
Primecap Management 30.55M $599.73M -0.8%
Aristotle Capital Management 29.45M $578.01M +0.1%
BLK Blackrock 28.31M $555.67M +8.0%
Sachem Head Capital Management 27.84M $546.41M 0.0%
TROW T. Rowe Price 22.28M $439M -35.4%
BAYRY Bayer Aktiengesellschaft 18.45M $538.64M 0.0%
Amundi 15.57M $305.35M +9.2%
BEN Franklin Resources 15.26M $299.52M +4.4%
Largest transactions Shares Bought/sold Change
Dodge & Cox 49.21M +20.62M +72.1%
TROW T. Rowe Price 22.28M -12.23M -35.4%
Vantage Investment Partners 2.51M -4.41M -63.7%
Ontario Teachers Pension Plan Board 6.73M +3.54M +110.8%
BK Bank Of New York Mellon 3.01M -3.23M -51.7%
Sculptor Capital 3.32M -2.52M -43.2%
MS Morgan Stanley 5.91M +2.52M +74.3%
Senator Investment 0 -2.5M EXIT
BLK Blackrock 28.31M +2.09M +8.0%
Kayne Anderson Rudnick Investment Management 10.26M -1.98M -16.2%

Financial report summary

Management Discussion
  • Management’s discussion and analysis of financial condition and results of operations (MD&A) is intended to assist the reader in understanding and assessing significant changes and trends related to our results of operations and financial position. This discussion and analysis should be read in conjunction with the consolidated financial statements and accompanying footnotes in Item 8 of Part II of this Form 10-K. Certain statements in this Item 7 of Part II of this Form 10-K constitute forward-looking statements. Various risks and uncertainties, including those discussed in "Forward-Looking Statements" and Item 1A, “Risk Factors,” may cause our actual results, financial position, and cash generated from operations to differ materially from these forward-looking statements. For results of operations discussions related to years ending December 31, 2020 and 2019, refer to Item 7 of Part II in our Annual Report on Form 10-K for the year ended December 31, 2020 filed with the Securities and Exchange Commission on March 1, 2021.
  • Elanco is a global animal health company that develops products for pets and farm animals in more than 90 countries. With a heritage dating back to 1954, we rigorously innovate to improve the health of animals and to benefit our customers while fostering an inclusive, cause-driven culture for our employees. We operate our business in a single segment directed at fulfilling our vision of enriching the lives of people through food, making protein more accessible and affordable, and through pet companionship, helping pets live longer, healthier lives.

Content analysis

H.S. freshman Good
New words: Aaron, America, ASC, beneficiary, BexCaFe, Codification, commodity, compound, diabetic, glucose, jurisdictional, oral, Overnight, owed, payout, power, reclassification, repeated, ruminant, Saffron, Schacht, significantly, slightly, SOFR, stranded, Supplementary, testified, unlimited, voluntarily
Removed: agreed, annum, borrowed, continuing, cooperate, covenant, customary, deferred, depreciation, EBITDA, enforcement, fiscal, floating, forma, governing, indenture, Investor, JPML, leverage, lien, maintain, maintenance, merge, Moody, newer, Poor, produced, rating, ratio, repaid, representing, Safron, subsequently, tested